entertainment -WSS

entertainment

author：fashion 2025-10-01 01:50:47 - browse：161

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Colorectal cancer study finds potential in overlooked immune cell

WSS

An Ebola outbreak presents a new mystery involving children

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Analysis of telehealth claims data suggest service duplication

Wegovy cuts risk of cardiovascular events by 20%, study finds

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

CDC launches VaccineFinder tool to locate Covid

Wildfire smoke exposes gaps in outdoor worker protections

When women are denied an abortion, their children fare worse than peers

Dobbs anniversary: the lost opportunity of abortion as health care

VC firm General Catalyst wants to buy a health system

Wildfire smoke exposes gaps in outdoor worker protections

Astronauts get first look at the spacecraft that will fly them around the moon

State Dept. review finds Biden bears some blame for Afghanistan failures

Zapping the brain for stroke rehab: Pivotal clinical trial begins

entertainment

Bill would stop addiction treatment from triggering child abuse inquiry

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Judge rejects Trump's counterclaim against E. Jean Carroll

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Lessons Learned: This is why you network to find that industry job you want

Chemotherapy drug shortage eases slightly but still widespread

focus

focus

knowledge

Wikipedia